Data completeness
0/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZLIN (azlocillin sodium) is an injectable antipseudomonal penicillin antibiotic developed by R-Pharm US currently in pre-launch stage. The drug is indicated for serious infections caused by susceptible gram-negative organisms including Pseudomonas aeruginosa. It works by inhibiting bacterial cell wall synthesis through beta-lactam mechanism of action.
Pre-Launch
As a pre-launch asset, this represents a greenfield commercial opportunity with potential for team expansion once regulatory approval is secured.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AZLIN at pre-launch stage offers high-impact opportunity to build a brand from ground zero in the hospital/infectious disease space. Success depends heavily on regulatory approval timing, hospital adoption strategy, and competitive differentiation in a crowded antimicrobial market.
Regulatory Affairs SpecialistCommercial Launch Manager
Worked on AZLIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.